A developmental safety study in rats using DHA- and ARA-rich single-cell oils

Arterburn, Linda M.; Boswell, K.; Henwood, Susan; Kyle, D. J.

doi:10.1016/s0278-6915(00)00067-3

Cited by 40 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ARA and DHA have been used for fortification of infant formulae in many parts of the world [22]. A range of companies have been marketing term infant formula and pre-term infant formula, containing single cell oils, in more than 30 and 60 countries worldwide, respectively.…”

Section: Markets For Single Cell Oilsmentioning

confidence: 99%

Omega-3/6 fatty acids: Alternative sources of production

Ward

Singh

2005

Process Biochemistry

566

325

View full text Add to dashboard Cite

Section: Markets For Single Cell Oilsmentioning

confidence: 99%

Omega-3/6 fatty acids: Alternative sources of production

Ward

Singh

2005

Process Biochemistry

566

325

View full text Add to dashboard Cite

“…Fatty acid methyl esters (FAMEs) were extracted and derived from freeze-dried biomass according to the method described elsewhere [15]. Injections of FAMEs in 1 lL volumes were separated on a GC fitted with a flameionizing detector and a FAMEWAX 30-meter column (0.25 mm i.d., 0.25 df) [16]. Eluted FAMEs were identified and quantified by comparison to authentic standards.…”

Section: Gas and High Pressure Liquid Chromatographymentioning

confidence: 99%

Characterization of Both Polyunsaturated Fatty Acid Biosynthetic Pathways in Schizochytrium sp.

Lippmeier¹,

Crawford²,

Owen³

et al. 2009

Lipids

129

View full text Add to dashboard Cite

Schizochytrium produces long chain polyunsaturated fatty acids (PUFAs) via a PUFA synthase. Targeted mutagenesis of one gene of this synthase was conducted to confirm PUFA synthase function and determine its metabolic necessity. The resulting mutants were auxotrophic and required supplementation with PUFAs. In vivo labeling experiments with radioactive fatty acids demonstrated the presence of several elongase and desaturase activities associated with the standard pathway of PUFA synthesis. However, this system was missing a critical Delta12 desaturase activity and was therefore not capable of synthesizing PUFAs from the 16- or 18-carbon saturated fatty acid products of the fatty acid synthase. Because Schizochytrium uses a PUFA synthase system for the production of PUFAs, the existence of a partial desaturase-elongase system (if not a simple vestige) is suggested to be either a scavenging mechanism for intermediate fatty acids prematurely released by the PUFA synthase or for PUFAs found in the organism's native environment.

show abstract

“…These studies consistently show increases in plasma and erythrocyte levels of DHA when infants receive formulas fortified with DHASCO-T oil and when adults and children were supplemented with DHASCO-T oil capsules. This algal oil has been widely tested for safety [36][37][38][39][40][41], and the US FDA has affirmed DHASCO-T as Generally Recognized As Safe (GRAS) for use in infant formula when combined with a fungal-derived arachidonic acid, ARASCO 2 (20:4n-6, ARA) oil [42].…”

Section: Introductionmentioning

confidence: 99%

Bioequivalence of Docosahexaenoic Acid from Different Algal Oils in Capsules and in a DHA‐Fortified Food

Arterburn¹,

Oken

Hoffman³

et al. 2007

Lipids

117

View full text Add to dashboard Cite

Docosahexaenoic acid (DHA), a long-chain omega-3 fatty acid, is important for eye and brain development and ongoing visual, cognitive, and cardiovascular health. Unlike fish-sourced oils, the bioavailability of DHA from vegetarian-sourced (algal) oils has not been formally assessed. We assessed bioequivalence of DHA oils in capsules from two different algal strains versus bioavailability from an algal-DHA-fortified food. Our 28-day randomized, placebo-controlled, parallel group study compared bioavailability of (a) two different algal DHA oils in capsules ("DHASCO-T" and "DHASCO-S") at doses of 200, 600, and 1,000 mg DHA per day (n = 12 per group) and of (b) an algal-DHA-fortified food (n = 12). Bioequivalence was based on changes in plasma phospholipid and erythrocyte DHA levels. Effects on arachidonic acid (ARA), docosapentaenoic acid-n-6 (DPAn-6), and eicosapentaenoic acid (EPA) were also determined. Both DHASCO-T and DHASCO-S capsules produced equivalent DHA levels in plasma phospholipids and erythrocytes. DHA response was dose-dependent and linear over the dose range, plasma phospholipid DHA increased by 1.17, 2.28 and 3.03 g per 100 g fatty acid at 200, 600, and 1,000 mg dose, respectively. Snack bars fortified with DHASCO-S oil also delivered equivalent amounts of DHA on a DHA dose basis. Adverse event monitoring revealed an excellent safety and tolerability profile. Two different algal oil capsule supplements and an algal oil-fortified food represent bioequivalent and safe sources of DHA.

show abstract

A developmental safety study in rats using DHA- and ARA-rich single-cell oils

Cited by 40 publications

References 29 publications

Omega-3/6 fatty acids: Alternative sources of production

Omega-3/6 fatty acids: Alternative sources of production

Characterization of Both Polyunsaturated Fatty Acid Biosynthetic Pathways in Schizochytrium sp.

Bioequivalence of Docosahexaenoic Acid from Different Algal Oils in Capsules and in a DHA‐Fortified Food

Contact Info

Product

Resources

About